Akari Therapeutics changes ADS ratio to maintain Nasdaq listing

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. SPY
3. FLG
4. GMAB
5. ACCV
6. QQQ
7. TSLA
8. SPCX
9. XNCR
10. AZN

Go back to Akari Therapeutics changes ADS ratio to maintain Nasdaq listing

Akari Therapeutics Announces ADS Ratio Change

March 17, 2026 4:30 PM EDT

TAMPA, Fla. and LONDON, March 17, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, today announced that the Company will change the ratio of its American Depositary Shares (ADSs) to ordinary shares from one ADS representing two thousand (2,000) ordinary shares to a new ratio of one ADS representing eighty thousand (80,000) ordinary shares. The ratio change is expected to be effective on March 31, 2026.

The ratio change is intended to enable Akari to maintain compliance with... More